Description
The ratio matters. The physiological plasma ratio of myo-inositol to D-chiro-inositol is approximately 40:1, and the RCT literature on PCOS outcomes has specifically studied this combination rather than myo-inositol alone. Myo-inositol acts as a second messenger in insulin signaling and FSH receptor pathways; D-chiro-inositol supports insulin-mediated glucose uptake through a distinct intracellular pathway. They’re complementary, not redundant, and the research supports using them together at this ratio rather than high-dose myo alone. This formula delivers 2000mg myo with 50mg DCI — the 40:1 ratio in the dose range that appears consistently across the published trials on ovarian function, cycle regularity, and metabolic markers in PCOS.
The cofactor and botanical additions address the parts of the PCOS picture that inositol doesn’t cover alone. Chromium picolinate supports healthy insulin sensitivity through a separate mechanism. Vitamin D3 at 1000 IU is included because D deficiency is common in women with PCOS and the research on D3 in this population spans insulin sensitivity, ovarian function, and cycle regularity. Zinc supports ovarian function and androgen metabolism. The botanical piece is where I get specific with patients: spearmint leaf has randomized trial evidence for reducing free testosterone in women with hirsutism and PCOS — it’s underused clinically and one of the more compelling inclusions here. Fenugreek supports insulin sensitivity and blood sugar regulation. Nettle root binds SHBG with potential effects on free androgen availability. Green tea extract adds EGCG-driven insulin sensitizing and antioxidant activity. I use this as the foundational PCOS formula and layer additional support depending on whether the patient’s primary complaint is metabolic, androgenic, or cycle-related.
